Mani Mohindru

CEO • Novasenta

Dr. Mohindru has served as Novasenta’s Chief Executive Officer and Director since April 2021. Dr. Mohindru also serves as a member of the board of directors of CytomX Therapeutics and Cardiff Oncology. Prior to Novasenta, she has held senior leadership positions in the biotech industry, having served as Chief Executive Officer of CereXis, Inc. (private), Chief Financial Officer and Chief Strategy Officer of Cara Therapeutics, Inc. (public), and Chief Strategy Officer of Curis, Inc (public).

Prior to her leadership roles in the biotechnology industry, Dr. Mohindru spent several years as an equity research analyst covering the biotechnology sector at UBS, Credit Suisse and ThinkEquity. She also co-founded a private biotechnology company and was a healthcare industry consultant. On the non-profit side, she is a member of the Executive Advisory Board of the Chemistry of Life Processes Institute of Northwestern University and a member of the Scientific Investment Advisory Committee of the Gates Center of Regenerative Medicine at the University of Colorado.

Dr. Mohindru received her Ph.D. in Neurosciences from Northwestern University and her Masters in Biotechnology and BS in Human Biology (Hons) from the All India Institute of Medical Sciences, India.